Enanta Pharmaceuticals (NASDAQ:ENTA) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research report sent to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $20.00 target price on the biotechnology company’s stock.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, January 21st. JPMorgan Chase & Co. began coverage on shares of Enanta Pharmaceuticals in a research note on Friday, November 14th. They set an “overweight” rating and a $17.00 price target on the stock. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Enanta Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $20.33.

Enanta Pharmaceuticals Trading Up 2.2%

Shares of NASDAQ ENTA opened at $14.13 on Tuesday. The company has a market capitalization of $410.05 million, a price-to-earnings ratio of -4.42 and a beta of 0.98. Enanta Pharmaceuticals has a twelve month low of $4.09 and a twelve month high of $17.15. The firm has a 50-day moving average of $14.11 and a two-hundred day moving average of $11.39.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, February 9th. The biotechnology company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.12. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 90.35%. The business had revenue of $18.62 million during the quarter, compared to the consensus estimate of $16.14 million. As a group, research analysts predict that Enanta Pharmaceuticals will post -4.65 earnings per share for the current year.

Insider Buying and Selling

In other Enanta Pharmaceuticals news, insider Yat Sun Or sold 2,390 shares of the company’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $14.23, for a total transaction of $34,009.70. Following the transaction, the insider owned 371,392 shares of the company’s stock, valued at approximately $5,284,908.16. This represents a 0.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tara Lynn Kieffer sold 2,106 shares of the firm’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $29,968.38. Following the completion of the transaction, the insider owned 30,620 shares in the company, valued at approximately $435,722.60. This represents a 6.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 11,961 shares of company stock worth $170,149 in the last quarter. Insiders own 11.48% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ENTA. AQR Capital Management LLC raised its stake in Enanta Pharmaceuticals by 674.7% in the 1st quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock valued at $1,971,000 after acquiring an additional 311,010 shares during the period. Millennium Management LLC increased its stake in Enanta Pharmaceuticals by 50.2% during the 1st quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after acquiring an additional 449,945 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Enanta Pharmaceuticals by 5.3% in the first quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company’s stock worth $720,000 after purchasing an additional 6,549 shares during the period. CWM LLC increased its holdings in Enanta Pharmaceuticals by 22.1% in the 2nd quarter. CWM LLC now owns 21,464 shares of the biotechnology company’s stock valued at $162,000 after buying an additional 3,879 shares during the period. Finally, Bank of Montreal Can increased its stake in Enanta Pharmaceuticals by 32.8% in the second quarter. Bank of Montreal Can now owns 33,868 shares of the biotechnology company’s stock valued at $256,000 after acquiring an additional 8,365 shares during the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.